Sign In
Buy MIRM
$91.84
-0.335 (-0.363%)
At Close: Jun 03, 2026
Mirum Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
04:04pm, Monday, 06'th Jan 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference.
Mirum Pharma: Buy At Dips For Volixibat Potential
10:00am, Wednesday, 25'th Dec 2024
Mirum Pharma has three approved products and a promising pipeline, with volixibat showing superior interim data for PBC compared to competitors. It is a buy for volixibat's potential, which is 2-3 yea
Why Is Mirum Pharmaceuticals (MIRM) Down 0.7% Since Last Earnings Report?
12:36pm, Thursday, 12'th Dec 2024
Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock?
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06:00pm, Tuesday, 10'th Dec 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Mirum Shares Surge More Than 90% in 6 Months: Here's Why
11:01am, Friday, 29'th Nov 2024
MIRM's lead drug, Livmarli, is driving revenues and the momentum is likely to continue. The company's efforts to build its pipeline beyond Livmarli also hold promise.
Mirum Pharmaceuticals, Inc. (MIRM) Q3 2024 Earnings Call Transcript
01:51pm, Tuesday, 12'th Nov 2024
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM ) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Andrew McKibben - Vice President, Investor Relations Chris Peetz - Chief E
Mirum's Q3 Earnings Beat Estimates, 2024 Revenue View Raised
12:45pm, Tuesday, 12'th Nov 2024
MIRM's third-quarter 2024 earnings and revenues surpass estimates. The company increases revenue guidance for 2024.
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Tops Revenue Estimates
10:15am, Tuesday, 12'th Nov 2024
Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.57 per share a year ago.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06:30pm, Friday, 08'th Nov 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
04:30pm, Thursday, 07'th Nov 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences.
Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024
04:30pm, Monday, 04'th Nov 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024.
Will Mirum Pharmaceuticals, Inc. (MIRM) Report Negative Q3 Earnings? What You Should Know
11:05am, Thursday, 31'st Oct 2024
Mirum Pharmaceuticals (MIRM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting
08:30am, Thursday, 31'st Oct 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #alagillesyndrome--Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting .
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:30pm, Thursday, 10'th Oct 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Volixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary Cholangitis
08:30am, Thursday, 10'th Oct 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #pbc--Volixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary Cholangitis.
